This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

George R. Prout, Jr, MD; Barbara Bassil, MD; Pamela Griffin, RN

Arch Surg. 1986;121(12):1463-1468.

Abstract
• One hundred sixty patients with grade 1 transitional-cell carcinoma of the bladder were evaluated and treated at the Massachusetts General Hospital, Boston. The mean follow-up period was 57 months. There were 92 new patients and 68 patients who had a history of transitional-cell carcinoma. Fifty-three patients (33%) never had another transitional-cell carcinoma. Sixty-eight (43%) of the remaining 107 patients had recurrent Ta grade 1 transitional-cell carcinoma. In 32 patients (20%) disease progressed in grade, in seven patients (4%) invasive transitional-cell carcinoma developed, five patients underwent cystectomy, and one patient died of transitional-cell carcinoma. High-risk factors included positive results of cytologic studies after therapy and three or more recurrences. Multiple therapies were used, but it is impossible to determine if anything other than transurethral resection altered the course in these patients. The data suggest that patients with low-risk factors and Ta grade 1 tumors might be followed up with a quarterly cytologic examination and cystoscopy once or twice a year, unless a change in symptoms occurs.

(Arch Surg 1986;121:1463-1468)

Author Affiliations
From the Urological Service, Massachusetts General Hospital (Drs Prout and Bassil and Ms Griffin), and the Department of Surgery, Harvard Medical School (Drs Prout and Bassil), Boston.

Footnotes
Accepted for publication Aug 14, 1986.

Read before the 39th Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 14, 1986.

Reprint requests to Urological Service, Massachusetts General Hospital, Fruit St, Boston, MA 02114 (Dr Prout).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems
Oosterhuis et al.
J. Clin. Pathol. 2002;55:900-905.
ABSTRACT | FULL TEXT  

Focal Loss of CD44 Variant Protein Expression is Related to Recurrence in Superficial Bladder Carcinoma
Toma et al.
Am. J. Pathol. 1999;155:1427-1432.
ABSTRACT | FULL TEXT